{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06295796",
            "orgStudyIdInfo": {
                "id": "8527-008"
            },
            "secondaryIdInfos": [
                {
                    "id": "MK-8527-008",
                    "type": "OTHER",
                    "domain": "Merck"
                }
            ],
            "organization": {
                "fullName": "Merck Sharp & Dohme LLC",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)",
            "officialTitle": "An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MK-8527 in Participants With Moderate and Severe Renal Impairment",
            "therapeuticArea": [
                "Nephrology and Renal Diseases"
            ],
            "study": "a-study-of-mk-in-participants-with-moderate-and-severe-renal-impairment-mk"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06-20",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-04-21",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-04-21",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-29",
            "studyFirstSubmitQcDate": "2024-02-29",
            "studyFirstPostDateStruct": {
                "date": "2024-03-06",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-25",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Merck Sharp & Dohme LLC",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The goal of this study is to evaluate the effect of moderate and severe renal impairment (RI) on the pharmacokinetics (PK), safety, and tolerability of MK-8527. There will be no hypothesis testing in the study."
        },
        "conditionsModule": {
            "conditions": [
                "Renal Impairment"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 18,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Moderate Renal Impairment",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with moderate renal impairment receive a single dose of MK-8527 on Day 1.",
                    "interventionNames": [
                        "Drug: MK-8527"
                    ]
                },
                {
                    "label": "Severe Renal Impairment",
                    "type": "EXPERIMENTAL",
                    "description": "Participants with severe renal impairment receive a single dose of MK-8527 on Day 1.",
                    "interventionNames": [
                        "Drug: MK-8527"
                    ]
                },
                {
                    "label": "Healthy",
                    "type": "EXPERIMENTAL",
                    "description": "Healthy participants receive a single dose of MK-8527 on Day 1.",
                    "interventionNames": [
                        "Drug: MK-8527"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "MK-8527",
                    "description": "Oral Capsule",
                    "armGroupLabels": [
                        "Healthy",
                        "Moderate Renal Impairment",
                        "Severe Renal Impairment"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Area under the concentration versus time curve from time 0 to last quantifiable sample (AUC0-last) of MK-8527 in plasma",
                    "description": "AUC0-last of MK-8527 in plasma will be determined.",
                    "timeFrame": "Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose"
                },
                {
                    "measure": "Area under the concentration versus time curve from time 0 to infinity (AUC0-inf) of MK-8527 in plasma",
                    "description": "AUC0-inf of MK-8527 in plasma will be determined.",
                    "timeFrame": "Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose"
                },
                {
                    "measure": "Maximum concentration (Cmax) of MK-8527 in plasma",
                    "description": "Cmax of MK-8527 in plasma will be determined.",
                    "timeFrame": "Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose"
                },
                {
                    "measure": "Time to Maximum concentration (Tmax) of MK-8527 in plasma",
                    "description": "Tmax of MK-8527 in plasma will be determined.",
                    "timeFrame": "Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose"
                },
                {
                    "measure": "Apparent terminal half-life (t1/2) of MK-8527 in plasma",
                    "description": "t1/2 of MK-8527 in plasma will be determined.",
                    "timeFrame": "Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose"
                },
                {
                    "measure": "Apparent Clearance (CL/F) of MK-8527 in plasma",
                    "description": "CL/F of MK-8527 in plasma will be determined.",
                    "timeFrame": "Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose"
                },
                {
                    "measure": "Apparent volume of distribution during terminal phase (Vz/F) of MK-8527 in plasma",
                    "description": "Vz/F of MK-8527 in plasma will be determined.",
                    "timeFrame": "Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, and 168 hours post dose"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of participants who experience one or more adverse events (AEs)",
                    "description": "An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.",
                    "timeFrame": "Up to approximately 29 days"
                },
                {
                    "measure": "Number of participants who discontinue study due to an AE",
                    "description": "An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.",
                    "timeFrame": "Up to approximately 29 days"
                },
                {
                    "measure": "AUC0-last of MK-8527-triphosphate (TP) in peripheral blood mononuclear cells (PBMCs)",
                    "description": "AUC0-last of MK-8527-TP in PBMCs will be determined.",
                    "timeFrame": "Predose, 4, 12, 24, 48, 96, 120, 144, 168, 336, 504, 672 hours post dose"
                },
                {
                    "measure": "AUC0-inf of MK-8527-TP in PBMCs",
                    "description": "AUC0-inf of MK-8527-TP in PBMCs will be determined.",
                    "timeFrame": "Predose, 4, 12, 24, 48, 96, 120, 144, 168, 336, 504, 672 hours post dose"
                },
                {
                    "measure": "Cmax of MK-8527-TP in PBMCs",
                    "description": "Cmax of MK-8527-TP in PBMCs will be determined.",
                    "timeFrame": "Predose, 4, 12, 24, 48, 96, 120, 144, 168, 336, 504, 672 hours post dose"
                },
                {
                    "measure": "Concentration at 168 hours (C168) of MK-8527-TP in PBMCs",
                    "description": "C168 of MK-8527-TP in PBMCs will be determined.",
                    "timeFrame": "168 hours post dose"
                },
                {
                    "measure": "Concentration at 672 hours (C672) of MK-8527-TP in PBMCs",
                    "description": "C672 of MK-8527-TP in PBMCs will be determined.",
                    "timeFrame": "672 hours post dose"
                },
                {
                    "measure": "Tmax of MK-8527-TP in PBMCs",
                    "description": "Tmax of MK-8527-TP in PBMCs will be determined.",
                    "timeFrame": "Predose, 4, 12, 24, 48, 96, 120, 144, 168, 336, 504, 672 hours post dose"
                },
                {
                    "measure": "t1/2 of MK-8527-TP in PBMCs",
                    "description": "t1/2 of MK-8527-TP in PBMCs will be determined.",
                    "timeFrame": "Predose, 4, 12, 24, 48, 96, 120, 144, 168, 336, 504, 672 hours post dose"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\nModerate and Severe RI\n\n* With the exception of RI, is in sufficient health for study participation.\n* Has stable renal function.\n\nHealthy\n\n* Matches mean age to participants with moderate and severe RI.\n* Has normal renal function.\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\nAll participants\n\n* History of cancer (malignancy).\n* Positive test results for Human-immunodeficiency virus (HIV), Hepatitis B surface antigen (HBsAg), or Hepatitis C virus (HCV).\n* Had a major surgery or lost significant volume of blood within 56 days prior to dosing.\n* Donated plasma within 7 days prior to dosing.\n\nModerate and Severe RI\n\n* Failed renal transplant or had a nephrectomy.\n* End stage renal disease requiring dialysis.\n* Any significant arrhythmia or conduction abnormality.\n* Has non-sustained or sustained ventricular tachycardia.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "75 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Toll Free Number",
                    "role": "CONTACT",
                    "phone": "1-888-577-8839",
                    "email": "Trialsites@merck.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Medical Director",
                    "affiliation": "Merck Sharp & Dohme LLC",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Research by Design ( Site 0001)",
                    "status": "RECRUITING",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60643",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Study Coordinator",
                            "role": "CONTACT",
                            "phone": "773-770-4824"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Merck Clinical Trials Information",
                    "url": "http://www.merckclinicaltrials.com"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf",
            "url": "http://engagezone.msd.com/ds_documentation.php"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000051437",
                    "term": "Renal Insufficiency"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007674",
                    "term": "Kidney Diseases"
                },
                {
                    "id": "D000014570",
                    "term": "Urologic Diseases"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M26718",
                    "name": "Renal Insufficiency",
                    "asFound": "Renal Impairment",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10698",
                    "name": "Kidney Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17319",
                    "name": "Urologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}